Published on in Vol 11, No 10 (2022): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/42585, first published .
Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial

Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial

Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial

Journals

  1. Corneli A, Perry B, Des Marais A, Choi Y, Chen H, Lilly R, Ayers D, Bennett J, Kestner L, Meade C, Sachdeva N, McKellar M. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduction Journal 2022;19(1) View
  2. Khati A, Copenhaver M, Xu R, Altice F, Wickersham J, Gautam K, Paudel K, Shrestha R. Oral pre-exposure prophylaxis (PrEP) receipt and persistence among opioid-dependent people who inject drugs initiating PrEP for HIV prevention. Journal of Substance Use and Addiction Treatment 2025;173:209693 View
  3. Sullivan M, Davis M, O’Cleirigh C, Batchelder A. PrEP Use Likelihood Among People Who Use Opioid Drugs: Understanding Clinical Correlates Along the Opioid Use Disorder Treatment Cascade. AIDS and Behavior 2025 View